Vaginal Atrophy (GSM): Treatment Options for Indian Women

• Vaginal atrophy is now called genitourinary syndrome of menopause (GSM) because it affects the vagina, vulva and urinary tract together.
• Symptoms include dryness, itching, burning, painful sex, light bleeding after sex, urinary urgency and recurrent UTIs.
• Roughly 40 to 70 percent of post-menopausal women have symptoms, but most Indian women wait years before raising it with a doctor.
• Moisturisers and lubricants help mild cases; low-dose vaginal oestrogen is the most effective treatment for moderate-to-severe GSM and has an excellent safety profile.
• GSM is progressive and does not reverse on its own, so earlier treatment prevents years of avoidable discomfort.
• Treatment is usually long-term maintenance, similar to managing blood pressure, rather than a one-time course.

Throughout your reproductive years, oestrogen keeps the vagina, vulva and urinary tract thick, elastic and well-lubricated. It also feeds the friendly lactobacilli bacteria that keep the vaginal pH acidic (around 3.5 to 4.5), which is your body's natural defence against infection.

After menopause, oestrogen falls to low levels. Without that signal, the vaginal walls thin out, lose their stretchy folds, and produce less lubrication. The pH rises, friendly bacteria decline, and the urethra and bladder tissues thin in parallel. Doctors group all of these changes under one umbrella term: genitourinary syndrome of menopause, or GSM.

The key thing to understand is that GSM is different from hot flashes and night sweats. Those vasomotor symptoms usually ease over four to seven years even without treatment. GSM works the opposite way: the tissue changes tend to build year on year unless oestrogen support is restored. This is exactly why it is worth treating sooner rather than waiting it out. You can read more on the underlying tissue inflammation in our piece on atrophic vaginitis after menopause.

GSM symptoms fall into three groups, and you may have strong symptoms in one group and almost none in another. That is one reason it often gets missed, since a woman may mention only her most bothersome single complaint rather than the whole pattern.

Because the symptoms overlap with infections and other conditions, it helps to know the full picture so you can describe it accurately to your doctor.

Diagnosis is mostly clinical. An experienced gynaecologist can usually recognise GSM in a single visit, based on your symptoms and a gentle vaginal examination that shows pale, thin, easily-bleeding tissue, loss of the natural folds, and a raised vaginal pH on a simple test strip.

A vaginal swab may be taken to rule out an infection that could be adding to your symptoms. Detailed lab tests are rarely needed for routine care. In India, a private gynaecology visit with examination and a basic swab typically costs around 500 to 1500 rupees.

The real barrier is not the test, it is the conversation. Many Indian women have symptoms for two to four years before mentioning them, often out of embarrassment. Those are years of progression that earlier treatment could have prevented. If raising it feels hard, our guide on how to talk to a doctor about vaginal pain can help you find the words.

For mild GSM, vaginal lubricants and moisturisers are the first step, and they remain useful alongside every other treatment. They work without hormones, so they suit women who prefer to avoid oestrogen or cannot use it.

It helps to know the difference. Lubricants are used at the time of sex to reduce friction and pain. Moisturisers are used regularly, every two to three days, to keep the tissue hydrated regardless of sexual activity. For more on choosing and using a lubricant well, see our guide to lubrication during sex.

Low-dose vaginal oestrogen is the single most effective treatment for moderate-to-severe GSM, and it has been well studied over decades. Applied directly to the vaginal tissue, it restores thickness, elasticity, blood flow, lubrication and the protective acidic environment, all at a tiny fraction of the dose used in systemic hormone therapy.

Crucially, very little is absorbed into the bloodstream. Serum oestrogen typically stays within the post-menopausal range, which is why low-dose vaginal oestrogen does not need the added progesterone that systemic hormone therapy requires to protect the womb lining. For a deeper look at how the cream itself is used, see our guide to vaginal oestrogen cream.

Available forms in India include estradiol vaginal tablets (Vagifem, Yuvafem; often imported, around 1500 to 3500 rupees a month) and estriol or conjugated-oestrogen vaginal creams (Premarin, local estriol such as Evalon; around 400 to 2000 rupees a month). The usual pattern is nightly for the first two weeks, then twice a week for maintenance.

Improvement is gradual but reliable: dryness often eases within 2 to 4 weeks, painful sex within 4 to 8 weeks, and urinary symptoms within 8 to 12 weeks, with full benefit over 3 to 6 months. Because symptoms return within months of stopping, treatment is usually continued long-term. Major bodies including the North American Menopause Society and the Indian Menopause Society support long-term use without a fixed time limit, as large studies have not shown an increased risk of breast cancer, womb cancer, clots or stroke at these doses.

Systemic hormone replacement therapy (oral or skin-patch oestrogen, with progesterone if you still have your womb) also treats vaginal atrophy, relieving it in around 75 to 90 percent of women. It is the right choice when you have bothersome hot flashes and night sweats alongside the vaginal symptoms, because it tackles everything in one regimen.

The trade-off is that systemic HRT carries the broader considerations that local oestrogen does not, such as small absolute increases in clot and stroke risk with oral forms. If vaginal dryness is genuinely your only significant complaint, low-dose vaginal oestrogen is usually the better, lower-exposure choice.

The two are not mutually exclusive. Some women on systemic HRT still add a little vaginal oestrogen for stubborn local symptoms without meaningfully changing their overall risk. The right path depends on your full picture and can change over time, so it is a decision to make with your doctor. Our detailed breakdown of HRT options and costs in India covers the systemic side in full.

For women who cannot or prefer not to use oestrogen, several non-hormonal options exist, though the evidence varies.

Vaginal laser therapy (CO2 fractional laser, marketed as MonaLisa Touch or FemiLift) is offered at some urban Indian private clinics, typically three sessions at around 25,000 to 60,000 rupees each. Early results looked promising, but more recent randomised trials have been mixed, and the US FDA cautioned against unregulated use in 2018. Major menopause societies do not recommend it as a first-line treatment, so it is best considered only after moisturisers and lubricants have failed and oestrogen is not an option.

Ospemifene (Osphena), an oral selective oestrogen receptor modulator for painful sex from GSM, and prasterone (vaginal DHEA) are approved in some countries but are not widely available in India and are expensive.

More accessible adjuncts include hyaluronic acid moisturisers, pelvic floor physiotherapy (around 800 to 2500 rupees a session in metro cities), and graduated vaginal dilators for women whose pain has led to muscle guarding. If discomfort has triggered involuntary tightening, our guides on Vaginismus: Causes, Symptoms and Treatment for Indian Women and on using vaginal dilators safely explain how to ease back gently.

The urinary symptoms of GSM are often what finally brings a woman to the doctor, yet they are frequently treated round after round without anyone naming the root cause. When the protective vaginal bacteria decline and pH rises, urinary bugs find it easier to take hold, which is why recurrent UTIs in post-menopausal women are so closely linked to GSM.

The evidence here is strong: regular low-dose vaginal oestrogen reduces UTI frequency by around 50 to 70 percent over 6 to 12 months. For a woman having three to five UTIs a year, that is a major change in quality of life and far less antibiotic use. Cranberry supplements are a low-risk add-on with modest evidence. Our guide to recurrent UTIs covers prevention in more depth.

For urgency and frequency, vaginal oestrogen helps alongside any specific bladder treatment. For leaking with a cough or sneeze, pelvic floor muscle training is the highest-value first step, with strong evidence; learn the technique in our guide to Kegel exercises for sexual and pelvic health. If leaking persists, see our piece on stress urinary incontinence for the next options, including pessaries and surgery.

The effect of GSM on intimacy is one of its most distressing parts, and one of the hardest to discuss. The progression is often quiet: occasional discomfort, then consistent pain, then anxiety, then avoidance, with months or years of unspoken distance before anyone names the medical cause.

The honest framing is that this is a treatable medical condition, not a relationship problem or the end of your sex life. Effective treatment restores comfort and lubrication in the great majority of women within 8 to 12 weeks. Lower desire that follows the discomfort usually improves too, as covered in our piece on libido changes during menopause.

It often helps to tell a partner plainly that the dryness is a hormonal issue with a clear treatment, not a loss of interest, since that unspoken fear is what many partners quietly assume. While treatment takes effect, generous lubricant, more time for arousal, and gentler positions all help maintain closeness. For couples resuming sex after a long gap, a gradual approach works best; see our guides on sex after menopause and on painful sex and dyspareunia.

Some situations need a tailored approach, and almost no woman is left without options.

Women with a history of oestrogen-receptor-positive breast cancer were traditionally told to avoid vaginal oestrogen. The current position is more nuanced: cohort studies have not shown increased recurrence with low-dose vaginal oestrogen, and major societies now support considering it for severe GSM after non-hormonal options have failed and oncology has been consulted. The conservative path is to maximise moisturisers and lubricants first. Women on aromatase inhibitors (anastrozole, letrozole, exemestane) often have especially severe atrophy and benefit from this individualised discussion. If you are navigating cancer care, our overview of breast cancer detection and treatment provides context.

Women with a history of womb cancer follow a similarly cautious, non-hormonal-first approach. Women with a history of blood clots are generally not candidates for systemic HRT, but low-dose vaginal oestrogen is considered safe because so little is absorbed. Women with vulval skin conditions such as lichen sclerosus often need combined care from gynaecology and dermatology.

GSM treatment rewards patience and consistency. Dryness usually eases within 2 to 4 weeks, painful sex within 4 to 8 weeks, and urinary symptoms within 8 to 12 weeks, with the full benefit over 3 to 6 months as the tissue rebuilds. Setting these expectations early prevents giving up too soon. A simple weekly note of your symptoms makes the follow-up visit more useful.

If response feels inadequate, it is usually fixable rather than a reason to abandon treatment. Common culprits are dosing too infrequently, using treatment intermittently, judging too early at four weeks instead of twelve, continued harsh soaps or douching, or an unaddressed factor such as pelvic floor tension or a skin condition. A three-month review with your doctor is the standard checkpoint.

Long-term maintenance is the rule, because the tissue changes return when treatment stops. The realistic mental model is that managing GSM is part of ongoing menopausal health, much like keeping an eye on blood pressure or bone strength, rather than a short course that ends. An annual review is reasonable to confirm continued benefit.

Some symptoms need timely medical review rather than self-treatment, because conditions other than GSM can look similar and must be ruled out.

• The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society
• ACOG Practice Bulletin: Treatment of Urogenital Symptoms (Genitourinary Syndrome of Menopause)
• NHS: Menopause symptoms and treatment (vaginal dryness and HRT)
• Mayo Clinic: Vaginal atrophy (genitourinary syndrome of menopause)
• British Menopause Society: Urogenital health and vaginal oestrogen
• Indian Menopause Society: Clinical practice guidelines on menopause